뒤로
Abbisko Cayman Limited(02256.HK) 가격
02256.HK 주가 차트
ABBISKO-B (02256.HK)
Abbisko Cayman Limited
HK$0
0%
$0
장 종료: Jan 28, 16:00:00 HKT
아직 데이터 없음Earnings FAQ
02256.HK의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Abbisko Cayman Limited 02256.HK의 지난 분기 매출 실적은 어땠나요?
Abbisko Cayman Limited의 매출 추정치는 얼마인가요?
Abbisko Cayman Limited의 수익 품질 점수는 얼마인가요?
Abbisko Cayman Limited는 언제 수익을 보고하나요?
Abbisko Cayman Limited의 예상 수익은 얼마인가요?
Abbisko Cayman Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
--
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
2.6M
EPS(TTM)
0.25
배당수익률
--
시가총액
--
ABBISKO-B란 무엇인가요?
Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai and currently employs 226 full-time employees. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).